Cerus (NASDAQ:CERS) Announces Earnings Results

Cerus (NASDAQ:CERS) announced its quarterly earnings data on Monday. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01), FiscalAI reports. Cerus had a negative net margin of 7.58% and a negative return on equity of 26.85%. The business had revenue of $64.58 million during the quarter, compared to the consensus estimate of $59.31 million.

Here are the key takeaways from Cerus’ conference call:

• Cerus reported record product revenue in 2025 with total revenues of $233.8M (up 16% year-over-year) and reaffirmed 2026 product revenue guidance of $224–$228M, implying ~9–11% product revenue growth.
• Commercial momentum is broad-based — the U.S. platelet franchise remains the core (estimated mid-60s market share), IFC demand surged (volume +110% YoY) and the new BCA group purchasing agreement gives access to ~50% of U.S. blood supply to drive further adoption; the INT200 illuminator has CE mark approval with positive customer feedback and a planned PMA submission in mid-2026.
• Progress on the red blood cell program continues — TÜV SÜD has completed its review and the dossier is moving to ANSM (potential EU approval in H1 2027 if reviews go smoothly), while U.S. RedeS Phase 3 enrollment is complete with top-line results expected in Q4 2026.
• Product gross margin compressed to 51.5% in Q4 (from 53.9% a year earlier) due to higher IFC production costs, import tariffs and inflationary pressures, and management warns tariff uncertainty could continue to pressure 2026 margins.
• Profitability and liquidity improved — seven consecutive quarters of positive non‑GAAP adjusted EBITDA (full-year adjusted EBITDA $9.5M), a reduced GAAP net loss of $15.6M, and about $83M in cash and short-term investments at year-end 2025.

Cerus Stock Performance

NASDAQ:CERS opened at $2.18 on Wednesday. The business’s fifty day moving average price is $2.31 and its 200 day moving average price is $1.84. The firm has a market capitalization of $418.76 million, a PE ratio of -27.25 and a beta of 1.51. Cerus has a 12 month low of $1.12 and a 12 month high of $2.95. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.89 and a quick ratio of 1.29.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Wall Street Zen upgraded shares of Cerus from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. TD Cowen restated a “buy” rating on shares of Cerus in a research report on Monday, January 12th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold”.

Institutional Trading of Cerus

Several institutional investors and hedge funds have recently added to or reduced their stakes in CERS. AQR Capital Management LLC raised its position in shares of Cerus by 291.6% in the 1st quarter. AQR Capital Management LLC now owns 1,429,062 shares of the biotechnology company’s stock valued at $1,986,000 after purchasing an additional 1,064,133 shares in the last quarter. Kotler Kevin acquired a new stake in shares of Cerus in the 4th quarter worth about $2,084,000. Millennium Management LLC raised its holdings in shares of Cerus by 17.6% during the third quarter. Millennium Management LLC now owns 3,470,062 shares of the biotechnology company’s stock valued at $5,517,000 after buying an additional 519,301 shares during the last quarter. Qube Research & Technologies Ltd boosted its position in Cerus by 156.5% during the 2nd quarter. Qube Research & Technologies Ltd now owns 749,564 shares of the biotechnology company’s stock worth $1,057,000 after acquiring an additional 457,347 shares during the period. Finally, Algert Global LLC lifted its holdings in Cerus by 451.3% in the third quarter. Algert Global LLC now owns 509,636 shares of the biotechnology company’s stock worth $810,000 after purchasing an additional 417,200 shares during the period. 78.37% of the stock is owned by hedge funds and other institutional investors.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.